The Centers for Medicare & Medicaid Services this week released for comment a proposal that Medicare cover diagnostic laboratory tests that use Next Generation Sequencing for patients with a breast or ovarian cancer that may be inherited. The test used must be approved by the Food and Drug Administration, ordered by a treating physician for a patient not previously tested using NGS, and performed in a laboratory certified under the Clinical Laboratory Improvement Amendments program, among other requirements. Under the proposal, Medicare administrative contractors also could decide to cover the tests for patients with other cancers that may be inherited.

Related News Articles

Headline
The National Quality Forum’s Measure Applications Partnership today released the annual list of performance measures under consideration for use in hospital…
Headline
The Centers for Medicare…
Headline
The Medicare Part A deductible for inpatient hospital services will increase by $44 in calendar year 2020, to $1,408, the Centers for Medicare…
Headline
The AHA “strongly supports efforts to reduce fraud and abuse in the Medicare program,” but the Centers for Medicare…
Headline
AHA today urged the Centers for Medicare…
Headline
The Centers for Medicare & Medicaid Services late today issued a final rule that increases Medicare hospital outpatient prospective payment system rates.